Organisation paid for research Program year 2025 Source: CMS Open Payments

Childrens Wisconsin

Neither a doctor nor a teaching hospital

Research payments

$228,952

16 payments

Through program year 2025, Childrens Wisconsin is reported as receiving $228,952 in research payments, across 16 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $56,698 3
2024 Research $99,644 5
2023 Research $27,225 3
2022 Research $44,658 3
2021 Research $726 2

Breakdown

Who paid Research payments · program years 2021–2025
  1. Merck Sharp & Dohme Corporation $227,946 13 payments
  2. Pfizer Inc. $700 1 payment
  3. E.R. Squibb & Sons, L.L.C. $305 2 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sotatercept MK-7962 in Children from 1 to Less Than 18 Years of Age With PAH on Standard of Care $143,217 5 payments
  2. A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sotatercept MK-7962 in Children from 1 to Less Than 18 Years of Age With PAH on Standard of Care $48,858 1 payment
  3. A Phase 1, open-label, non-comparative, multicenter clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane,tazobactam MK-7625A in pediatric participants with nosocomial pneumonia $28,031 5 payments
  4. A Phase 1, open-label, non-comparative, multicenter clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane,tazobactam MK-7625A in pediatric participants with nosocomial pneumonia $5,375 1 payment
  5. A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sotatercept MK-7962 in Children from 1 to Less Than 18 Years of Age With PAH on Standard of Care $2,466 1 payment
  6. Openlabel Induction and Maintenance Study of Oral Cp690550 Tofacitinib in Children With Moderately to Severely Active Ulcerative Colitis $700 1 payment
  7. Phase I/IIA Pediatric Study (Indication TBD) - Phase 1/2 Study of Bempegaldesleukin in Combination with Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Malignancies (PIVOT IO 020) $279 1 payment
  8. Phase I IIA Pediatric Study Indication TBD $26 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record